U.S. Hyper-Personalized Medicine Market Growing Fast with AI and Genomic Innovations

A notable rise in cancer cases & neurodegenerative disorder instances, the market is highly demanding next-generation therapies, with enhanced efficacy, coupled with the wider use of AI solutions to assist in consistent monitoring.

Market Overview

The adoption of developing, advanced healthcare models to customize prevention, diagnosis, & treatment based on each unique genetic, molecular, lifestyle, & environmental data in real-time is termed the U.S. hyper-personalized medicine market. The market has a higher scope in the progression of tailored gene silencing, RNA interference, & CRISPR/Cas9 techniques for cancer, rare genetic disorders, & chronic issues. Also, shifting towards broader application of genomic sequencing, proteomics, & biomarker testing.

Market Projections

The U.S. companies will play a pivotal role in the development of digital twins, which comprise the use of large language models for assessing complex medical imaging. The company era will push the adoption of 3D printing to design tailored therapies customized to an individual’s accurate dosage & formulation requirements. The U.S. hyper-personalized medicine market will also have a chance in integrating wearable devices with AI to allow consistent monitoring & preventive care.

Approximate New Cases of Diseases in the U.S. Per Year (In Million)

To support the increasing cases of cancer & Alzheimer’s in the U.S, the market is promoting AI-powered diagnostics & molecularly matched therapies, which are transitioning from experimental phases into clinical practice, with emphasis on proactive, preventive care. Advanced cellular treatments & tailored therapies are going to be conveyed in outpatient settings or at home.

Market Segmentation Overview

• By product, the therapeutics segment led with a 35% share of the U.S. hyper-personalized medicine market. This significantly covers diverse targeted drug therapies, gene/cell therapies, RNA-based treatments, & neoantigen vaccines to support treating different cases of chronic illnesses. Incorporation of suitable regulatory landscapes, rising biopharma investment in research, is propelling the development of these therapeutics.
• By technology, the genomics segment dominated with 40% share of the market in 2025, due to the affordability of NGS, which fosters precision treatment. Also, the U.S. is experiencing surging demand for proactive, preventative health management, with wider adoption of molecular diagnostics for oncology, which drives at-home genetic testing & wellness profiling.
• By application, the oncology segment held a major share of 30% of the U.S. hyper-personalized medicine market in 2025. Kay catalysts are stepping towards targeted treatments to attack specific cancer cells & the use of AI algorithms in the expansion of biomarker discovery & analysis of vast datasets for tailored diagnosis. Alongside, the FDA is accelerating approvals for novel candidates, while leading firms are investing in the revolution of precision interventions in cancer instances.
• By end user, the hospitals segment registered dominance with 40% share of the market in 2025. These U.S. hospitals are extensively providing comprehensive care, including advanced diagnostics, improved interventions, & AI-driven approaches. They are also fostering the unification of AI-enabled diagnostic tools, electronic health record (EHR) decision assistance, & wearable devices for continuous monitoring.

Top Companies in the Hyper-Personalized Medicine Market

The top four firms of the market, such as Illumina, Inc., Guardant Health, Amgen, and AbbVie Inc., are increasingly transforming innovations in hyper-personalized medicine by using AI, genetic data, and companion diagnostics. Whereas Illumina, Inc. is dominating as the center to facilitate the foundational DNA sequencing technology required for hyper-personalized medicine.

Segments Covered in the Report  

By Product  

Diagnostics  

Genomic Sequencing 

Biomarker Testing 

Molecular Diagnostics  

Therapeutics  

Targeted Drug Therapies  

Gene And Cell Therapies  

RNA-based Therapeutics  

Medical Care 

Telemedicine 

Personalized Treatment  

AI Clinical Support  

Nutrition & Wellness 

Nutrigenomics 

Personalized Diets 

Microbiome Analysis  

By Technology 

Genomics 

Proteomics 

Bioinformatics  

Metabolomics 

Artificial Intelligence (AI) 

By Application 

Oncology 

Cardiology 

Neurology 

Immunology 

Rare Disorders 

Infectious Diseases  

By End User 

Hospitals  

Diagnostic Centers 

Research Institutes 

Clinics  

Others